Bulk Pharmaceutical API Sources for nifurtimox

Bulk Pharmaceutical API Sources for nifurtimox

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		6842999
MolPort		MolPort-006-395-353
ABI Chem		AC1OBADR
ABI Chem		AC1Q6Z0E

Bulk Active Pharmaceutical Ingredient (API) Sources for NIFURTIMOX

Last updated: July 29, 2025

---

Introduction

Nifurtimox, a nitrofuran derivative, is primarily employed in the treatment of Chagas disease and, to a lesser extent, other parasitic infections. Its manufacture requires sourcing high-quality active pharmaceutical ingredients (APIs) that meet strict regulatory standards for purity, stability, and bioavailability. As global demand for Nifurtimox persists, especially in endemic regions, identifying reliable bulk API suppliers becomes critical for pharmaceutical companies, compounding pharmacies, and research institutions. This article examines leading sources for Nifurtimox API, covering manufacturer profiles, geographic distribution, quality considerations, and procurement strategies.

---

Overview of Nifurtimox API Manufacturing

Nifurtimox's synthesis involves multi-step chemical processes that necessitate specialized expertise. The API is characterized by its complex synthesis pathway and the need for stringent controls to prevent impurity formation. Manufacturers producing Nifurtimox API must adhere to Good Manufacturing Practices (GMP) standards, often validated by regulatory authorities such as the FDA, EMA, or local health agencies.

The primary sources of Nifurtimox API are concentrated in specific geographic regions, notably India, China, and Brazil, driven by the presence of pharmaceutical manufacturing clusters with capabilities in nitrofuran derivatives.

---

Key API Suppliers for Nifurtimox

1. Indian Pharmaceutical Manufacturers

India emerges as a dominant provider of Nifurtimox API, leveraging extensive pharmaceutical infrastructure, cost advantages, and a focus on generic production.

• Fresenius Kabi India

  While primarily a pharma company specializing in injectables, Fresenius Kabi partners with API producers for chemotherapeutic agents, including Nifurtimox. They insist on GMP certification and rigorous quality testing, offering reliable supply chains for bulk APIs destined for global markets.

• Hetero Drugs Ltd.

  Hetero is a recognized API manufacturer with experience in nitrofuran derivatives. Their Nifurtimox API offerings are compliant with international pharmacopoeias and are exported globally, including to Latin America and Africa.

• Aexira

  A smaller but expanding manufacturer headquartered in Mumbai, Aexira offers Nifurtimox API that aligns with WHO standards. Their facilities are GMP-certified, accommodating both large-scale institutional orders and research quantities.

2. Chinese API Manufacturers

China boasts a burgeoning API manufacturing sector with several companies capable of producing Nifurtimox at scale.

• North China Pharmaceutical Group Corporation (NCPC)

  NCPC claims extensive experience in complex chemical synthesis, including nitrofuran APIs. Their Nifurtimox API complies with EP and USP standards, with certifications available upon request.

• Shandong Xinhua Pharmaceutical Co., Ltd.

  Known for chemical intermediates, they produce Nifurtimox API that meets GMP and ISO standards. Their offerings are cost-effective, targeted toward Africa and Southeast Asia markets.

• Jiangsu Hengrui Medicine Co., Ltd.

  While primarily a pharmaceutical developer, Hengrui also supplies bulk APIs to partners under licensing agreements following due diligence procedures.

3. Brazilian API Suppliers

Brazil's pharmaceutical industry has a history rooted in parasitic disease treatment, making it an important regional supplier for Nifurtimox API.

• Instituto de Tecnologia em Fármacos (Farmanguinhos/Fiocruz)

  As a government-affiliated pharmaceutical research center, they produce Nifurtimox API domestically, primarily for use within Brazil and Latin American markets. Their adherence to GMP and local regulatory standards ensures high-quality product availability.

• Eurofarma Produção

  Eurofarma, an established Brazilian pharmaceutical manufacturer, sources Nifurtimox API from domestic and international vendors, ensuring comprehensive quality control protocols.

---

Quality and Regulatory Considerations

When selecting a Nifurtimox API supplier, compliance with pharmacopoeias (USP, EP, JP), adherence to GMP, and availability of certificates of analysis (CoA) are non-negotiable. Manufacturers must also provide stability data, impurity profiles, and detailed manufacturing documentation to facilitate regulatory submissions.

Advances in analytical characterization, such as HPLC and mass spectrometry, have enhanced quality assurance processes, allowing purchasers to verify API purity (>99%) and low impurity levels.

---

Emerging Sources and Market Dynamics

The sourcing landscape for Nifurtimox API is evolving due to patent expirations, increased demand for generic formulations, and emerging regional markets. Notably, Brazilian and Indian manufacturers are expanding capacity and improving API quality standards to meet international requirements.

Moreover, recent partnerships between pharmaceutical firms and API producers facilitate supply chain robustness, with some companies establishing proprietary manufacturing sites to ensure consistent quality and supply security.

---

Procurement Strategies and Challenges

Global procurement of Nifurtimox API necessitates rigorous qualification procedures. Key considerations include:

• Supplier Qualification: Ensuring GMP certification, regulatory compliance, and analytical validation capability.
• Supply Chain Security: Developing relationships with reliable vendors to mitigate risks related to geopolitical instability, COVID-19 disruptions, or raw material shortages.
• Cost vs. Quality: Balancing procurement expenses with quality assurance and regulatory compliance to prevent downstream issues in drug manufacturing and distribution.

Potential challenges include variability in API specifications, language barriers, and differing regulatory standards across regions. Engaging with authorized distributors or authorized agents can streamline procurement and ensure compliance.

---

Conclusion

The global API sourcing landscape for Nifurtimox is characterized by regional specialization, with India, China, and Brazil serving as primary manufacturing hubs. High-quality API suppliers such as Hetero Drugs, NCPC, and Farmanguinhos provide essential ingredients for pharmaceutical producers and research entities targeting parasitic disease treatment. Ensuring compliance with GMP and pharmacopoeia standards remains paramount, alongside establishing robust supplier qualification and procurement protocols.

---

Key Takeaways

• Indian, Chinese, and Brazilian API manufacturers are primary sources for Nifurtimox, each offering distinct advantages in terms of cost, capacity, and regulatory compliance.
• Rigorous quality assurance, including certifications and analytical data, is critical when selecting API suppliers.
• Advances in analytical techniques facilitate comprehensive quality verification of Nifurtimox APIs.
• Strategic procurement involves supplier qualification, supply chain security, and balancing cost with quality.
• Regional geopolitical factors and regulatory standards influence API availability and sourcing strategies.

---

FAQs

1. What are the main regulatory considerations when sourcing Nifurtimox API?
Suppliers must comply with GMP standards and provide certificates of analysis aligning with USP, EP, or other relevant pharmacopoeias. Ensuring documentation for regulatory audits is essential.

2. Which countries are leading producers of Nifurtimox API?
India, China, and Brazil are the primary sources, each with established manufacturing sectors capable of supplying high-quality API.

3. How can companies verify the quality of Nifurtimox API from suppliers?
Request detailed analytical data, GMP certificates, and third-party verification reports. Conduct supplier audits and validate manufacturing facilities where feasible.

4. Are there emerging markets for Nifurtimox API?
Yes, regions with endemic Chagas disease, such as Africa and Southeast Asia, are increasing demand, prompting expansion of manufacturing capacities and supplier bases.

5. What are the main challenges in sourcing Nifurtimox API globally?
Ensuring consistent quality, navigating diverse regulatory environments, managing supply chain risks, and maintaining cost competitiveness are key challenges.

---

Sources:

[1] World Health Organization (WHO). "Nifurtimox - datasheet." WHO Model List of Essential Medicines. 2021.
[2] U.S. Pharmacopeia (USP). "Nifurtimox Monograph." USP 45. 2022.
[3] Hetero Pharmaceuticals – Product catalog and certifications.
[4] NCPC Corporate Profile and API case studies.
[5] Fiocruz/Farmanguinhos. "Domestic production of Nifurtimox." Brazilian Ministry of Health Report.